Abstract
Background:
Muscle symptoms in patients who are treated with statins and have normal creatine kinase levels are not well understood.
Objective:
To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use.
Design:
Case reports from preliminary analysis of an ongoing clinical trial.
Setting:
Clinical research center in a community hospital.
Patients:
Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use.
Measurements:
1] Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength.
Results:
All four patients repeatedly distinguished blinded statin therapy from placebo. Strength testing confirmed weakness during statin therapy that reversed during placebo use. Muscle biopsies showed evidence of mitochondrial dysfunction, including abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy when they were not receiving statins. Creatine kinase levels were normal in all four patients despite the presence of significant myopathy.
Conclusion:
Some patients who develop muscle symptoms while receiving statin therapy have demonstrable weakness and histopathologic findings of myopathy despite normal serum creatine kinase levels.
*For members of the Scripps Mercy Clinical Research Center, see the Appendix.
References
- 1.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57. [PMID: 9841303] CrossrefMedlineGoogle Scholar - 2.
- 3.
Sacks FM ,Pfeffer MA ,Moye LA ,Rouleau JL ,Rutherford JD ,Cole TG ,et al . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9. [PMID: 8801446] CrossrefMedlineGoogle Scholar - 4.
Farmer JA . Learning from the cerivastatin experience. Lancet. 2001;358:1383-5. [PMID: 11705478] CrossrefMedlineGoogle Scholar - 5.
England JD ,Walsh JC ,Stewart P ,Boyd I ,Rohan A ,Halmagyi GM . Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors—simvastatin and pravastatin [Letter]. Aust N Z J Med. 1995;25:374-5. [PMID: 8540887] CrossrefMedlineGoogle Scholar - 6.
Sinzinger H ,Schmid P ,O'Grady J . Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [Letter]. Atherosclerosis. 1999;143:459-60. [PMID: 10217378] MedlineGoogle Scholar - 7.
Ucar M ,Mjörndal T ,Dahlqvist R . HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22:441-57. [PMID: 10877038] CrossrefMedlineGoogle Scholar - 8.
Masters BA ,Palmoski MJ ,Flint OP ,Gregg RE ,Wang-Iverson D ,Durham SK . In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 1995;131:163-74. [PMID: 7878672] CrossrefMedlineGoogle Scholar - 9.
Nakahara K ,Kuriyama M ,Sonoda Y ,Yoshidome H ,Nakagawa H ,Fujiyama J ,et al . Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol. 1998;152:99-106. [PMID: 9772205] CrossrefMedlineGoogle Scholar - 10.
Marino M ,Nicholas JA ,Gleim GW ,Rosenthal P ,Nicholas SJ . The efficacy of manual assessment of muscle strength using a new device. Am J Sports Med. 1982;10:360-4. [PMID: 7180955] CrossrefMedlineGoogle Scholar - 11.
Dubowitz V . Muscle Biopsy—A Practical Approach. London: Bailliere Tindall; 1985. Google Scholar - 12.
Stubbs RJ ,Schwartz MS ,Gerson RJ ,Thornton TJ ,Bayne WF . Comparison of plasma profiles of lovastatin (mevinolin), simvastatin (epistatin) and pravastatin (epstatin) in the dog. Drug Invest. 1990;2Suppl 2 18-28. CrossrefGoogle Scholar - 13.
Gruer PJ ,Vega JM ,Mercuri MF ,Dobrinska MR ,Tobert JA . Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999;84:811-5. [PMID: 10513779] CrossrefMedlineGoogle Scholar - 14.
Gaist D ,Rodríguez LA ,Huerta C ,Hallas J ,Sindrup SH . Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-9. [PMID: 11505177] CrossrefMedlineGoogle Scholar - 15.
Lanctôt KL ,Naranjo CA . Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther. 1995;58:692-8. [PMID: 8529335] CrossrefMedlineGoogle Scholar - 16.
Raskind JY ,El-Chaar GM . The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother. 2000;34:630-8. [PMID: 10852092] CrossrefMedlineGoogle Scholar - 17.
Ogasahara S ,Engel AG ,Frens D ,Mack D . Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379-82. [PMID: 2928337] CrossrefMedlineGoogle Scholar - 18.
Phillips P ,Haas R ,Barshop B ,Bannykh S ,Amjadi D . Utility of abnormal 3-methylglutaconic aciduria (3MGA) in diagnosing statin associated myopathy. Atheroscler Thromb Vasc Biol Online Journal. 2002;22:878. Google Scholar - 19.
Scaglia F ,Sutton VR ,Bodamer OA ,Vogel H ,Shapira SK ,Naviaux RK ,et al . Mitochondrial DNA depletion associated with partial complex II and IV deficiencies and 3-methylglutaconic aciduria. J Child Neurol. 2001;16:136-8. [PMID: 11292221] CrossrefMedlineGoogle Scholar
Author, Article, and Disclosure Information
Paul S. Phillips,
From Scripps Mercy Hospital and University of California, San Diego, Medical Center, San Diego, California; and State University of New York at Buffalo, Buffalo, New York.
Acknowledgments: The authors thank Mr. David Cloutier for assistance with randomization sequencing and statistical analyses and Dr. Beatrice Golomb, Assistant Professor of Medicine, University of California, San Diego, for assistance with the analysis and development of epidemiologic evidence.
Disclosures:Grants pending: P.S. Phillips, R.H. Haas, S. Bannykh, S. Hathaway, N.L. Gray, B.J. Kimura.
Corresponding Author: Paul S. Phillips, MD, Interventional Cardiology, Scripps Mercy Hospital (MER 74), 4077 Fifth Avenue, San Diego, CA 92103; Web site, impostertrial.com; e-mail, inquire@impostertrial.
Current Author Addresses: Dr. Phillips: 4060 Fourth Avenue, Suite 205, San Diego, CA 92103.
Dr. Haas: University of California San Diego Medical Center, 9500 Gilman Drive, La Jolla, CA 92093-0935.
Dr. Bannykh: Division of Neuropathology, University of California San Diego Medical Center, 225 West Dickenson Avenue, San Diego, CA 92103.
Ms. Hathaway and Ms. Gray: Cardiology Research, Scripps Mercy Hospital (MER 74), 4077 Fifth Avenue, San Diego, CA 92103.
Dr. Kimura: 230 Prospect Place, Suite 250, Coronado, CA 92118.
Dr. Vladutiu: University at Buffalo, 936 Delaware Avenue, Buffalo, NY 14209.
Dr. England: Blue Mountains Hospital, Great Western Highway, Katoomba, NSW 2780, Australia.
Author Contributions: Conception and design: P.S. Phillips, R.H. Haas, S. Hathaway, N.L. Gray, B.J. Kimura, J.D.F. England.
Analysis and interpretation of the data: P.S. Phillips, R.H. Haas, S. Bannykh, B.J. Kimura, G.D. Vladutiu, J.D.F. England.
Drafting of the article: P.S. Phillips, R.H. Haas, S. Bannykh, J.D.F. England.
Critical revision of the article for important intellectual content: P.S. Phillips, R.H. Haas, S. Bannykh, S. Hathaway, N.L. Gray, B.J. Kimura, G.D. Vladutiu.
Final approval of the article: P.S. Phillips, R.H. Haas, S. Bannykh.
Provision of study materials or patients: R.H. Haas, B.J. Kimura, J.D.F. England.
Obtaining of funding: S. Hathaway, N.L. Gray.
Administrative, technical, or logistic support: S. Hathaway, N.L. Gray.
Collection and assembly of data: P.S. Phillips, R.H. Haas, S. Hathaway, N.L. Gray, G.D. Vladutiu.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.